PROGRAMS
Ubiquitin Drug Discovery and Diagnostics 2009 (ARCHIVE)
Date: October 13, 2009 — October 14, 2009
Location: Park Hyatt at the Bellevue (Philadelphia)
PROGRAMS DETAILS
Click to Download Brochure Conference Program AgendaRegistration- Grand Ballroom Foyer, 1st Floor
Breakfast, Breaks & Cocktail Reception- Red and Clover Rooms, 1st Floor
Sessions- Grand Ballroom, 1st Floor
Lunch- Grand Ballroom Balcony, 2nd Floor
Dinner- Grand Ballroom, 1st Floor
Tuesday, October 13, 2009
7:15am Registration
7:15am Poster Viewing and Continental Breakfast
8:15am Welcome by Conference Chair
8:30am Introduction for Keynote Speaker
Keynote Address
The Ubiquitin System: How It All Began
Dr. Aaron Ciechanover, Technion-Israel Institute of
Technology
SESSION 1- UBIQUITIN AND UBIQUITIN-LIKE PROTEINS
9.00am Introduction from Chair
Dr. Mark Hochstrasser, Yale University
Function and Mechanism of a SUMO-Targeted Ubiquitin-Ligase
Dr. Mark Hochstrasser, Yale University
9.30am Role of Ubiquitin Gene Networks in Autism Spectrum
Disorders
Dr. Hakon Hakonarson, Center for Applied Genomics, The
Children's Hospital of Philadelphia
9:50am Targeting E3 Ligases for Drug Discovery
Dr. Claudio Joazeiro, Scripps Research Institute
10:10am Chemistry of Proteolysis and Antigen Presentation
Dr. Huib Ovaa, Netherlands Cancer Institute
10:30am Coffee Break and Poster Viewing
SESSION 2- INFECTIOUS DISEASE: VIRAL AND BACTERIAL
11:00am Introduction from the Chair
Dr. Joseph Bolen, Millenium Pharmaceuticals
A Noncovalent Class of Papain-like
Protease/Deubiquitinase Inhibitors Blocks
SARS Virus Replication
Dr. Andrew Mesecar, University of Illinois at Chicago
11:30am Identification of a Small Molecule Inhibitor of PfSENP1, a
SUMO Deconjugating Protease of Plasmodium Falciparum
Dr. Matthew Bogyo, Stanford University School of Medicine
11:50am The Ubiquitin Pathway and Malaria
Dr. Karine Le Roch, University of California
Riverside
12:10pm Exploitations of the Host Ubiquitination System by
Pathogenic Bacteria
Dr. Daoguo Zhou, Purdue University
12:30pm Lunch and Poster Viewing
SESSION 3- EMERGING TARGETS IN ONCOLOGY
2:00pm Introduction from Chair
Dr. Keith D. Wilkinson, Emory University
How Does BAP1 Regulate the G1/S Transition? The Search
for Substrates
Dr. Keith Wilkinson, Emory University
2:30pm Strategy for the Design and Development of Ubiquitin-Like
Protein Activating Enzyme Inhibitors
Dr. James Brownell, Millenium Pharmaceuticals
3:00pm Discovery and Development of the Novel USP7 Inhibitor, P5091
Dr. Ben Nicholson, Progenra Inc.
3:30pm Coffee Break and Poster Viewing
4:00pm E3 Ligases and the Cell Cycle
Dr. Peter Jackson, Genentech Inc.
4:30pm USP34 Controls the Nuclear Localization of Axin to Positively Regulate Wnt/b-Catenin Signaling
Dr. Stephane Angers, University of Toronto
4:45pm Recent Progress Towards the Identification of Selective
Inhibitors of Ubiquitin Specific Proteases
Dr. Frederic Colland, Hybrigenics Pharma
5:00pm Business Roundtable
Round Table Discussion Groups (Attendees sign-up at the
registration desk)
(1) Biotech Pharma Partnership - How to Innovate in
Drug Development
Chair: Dr. Jack Geltosky, Consultant, Progenra, Inc.
Panel: Dr. Brenda Gavin, Founding Partner, Quaker
BioVentures
Dr. Randall Johnson, Former Senior Director,
Oncology, GSK
(2) The Ubiquitin Pathway and Novel Drug Targets
Chair: Dr. Joseph Bolen, Chief Scientific Officer,
Millennium Pharmaceuticals
Panel: Dr. Michael Mattern, COO, Progenra, Inc.
(3) Academia Industry Partnership- From Lab to Market
Chair: To be announced
Panel: To be announced
6:00pm Day 1 Adjourns
6:30pm Reception and Poster Viewing
7:30pm Dinner
Wednesday, October 14, 2009
7:15am Continental Breakfast and Poster Viewing
7:45am Introduction to the speaker
8:00am Pharma 2.0 and Translational Medicine
Dr. Preston Hensley, Lotus Consulting, Formally Senior
Director, Translational Medicine, Pfizer
SESSION 4- INFLAMMATION, MUSCLE WASTING AND NEURODEGENERATION
8:30am Introduction from Chair
Dr. Alfred Goldberg, Harvard Medical School
New Insights into the Excessive Protein Degradation
During Muscle Wasting and Cachexia
Dr. Alfred Goldberg, Harvard Medical School
9:00am Rhes – An Unique Regulator of SUMOylation, Mediates
mutant Huntingtin’s Toxicity
Dr. Srini Subramaniam, Johns Hopkins University
9:15am The Ubiquitin Ligase Muscle Ring Finger-1 (MuRF1)
Protects Against Cardiac Ischemia Reperfusion
Injury In-vivo
Dr. Monte Willis, University of North Carolina- Chapel
Hill
SESSION 5- CLINICAL PIPELINE
9:30 am Introduction from Chair
Dr. Kenneth C. Anderson, Dana Farber Cancer
Institute/Harvard Medical School
Current Status of Proteasome Inhibitor Therapy in
Multiple Myeloma
Dr. Kenneth C. Anderson, Dana Farber Cancer
Institute/Harvard Medical School
10:00am The Discovery and Characterization of CEP-18770- a
Novel Orally Active Boronic Acid Proteasome
Inhibitor
Dr. Bruce Ruggeri, Cephalon, Inc.
10:30am Coffee Break and Poster Viewing
11:00am Carfilzomib, a Selective and Irreversible Ketoepoxide-
based Proteasome Inhibitor
Dr. Mark Bennett, Proteolix, Inc.
11:30am In-Vitro and In-Vivo Evaluation of the Orally Active
Proteasome Inhibitor MLN9708 in Preclincal Models of
Human Cancer
Dr. Erik Kupperman, Millennium Pharmaceuticals
12:30pm Lunch and Poster Viewing
SESSION 6- BIOMARKERS AND DIAGNOSTICS
2:00pm Introduction
It is Time to Ubiquitinate Alzheimer Disease
Dr. Khalid Iqbal, NY State Institute for Basic Research in
Developmental Disabilities
2:30pm Challenges of Identifying Small Molecule Inhibitors of
Ubiquitin Ligases, an Emerging Therapeutic Target Class
Dr. Paul Andrews, Amgen Inc.
3:00pm Recognition and Remodeling of the Ubiquitin Landscape
at DNA Double Strand Breaks by BRCA1 Protein
Complexes
Dr. Roger Greenberg, University of Pennsylvania Medical
School
3:15pm Coffee Break and Poster Viewing
3:45pm Connecting Different Ubiquitin Chains to Diverse
Physiological Means- Polyubiquitin Chains Size, Type and
Time Matters
Dr. Manuel Rodriguez, CIC bioGUNE, Bizkaia, Spain
4:15pm Protease Targeting Strategies
Dr. Boris Turk, J Stefan Institute
4:45pm K63-linked Ubiquitination as a Target of Diagnosis and
Drug Discovery
Dr. Wei Xiao, University of Saskatchewan
5:00pm Conference Adjourns
